Novan, Inc. (NASDAQ:NOVN) Files An 8-K Regulation FD Disclosure
Item 7.01.
|
Regulation FD Disclosure. |
On April 12, 2017, Novan, Inc. (the Company) published a
corporate presentation on its website at www.Novan.com. The
corporate presentation is furnished herewith as Exhibit 99.1 to
this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information contained in, or incorporated into, this Item 7.01,
including the corporate presentation attached as Exhibit 99.1, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any of the Companys filings under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
See the Exhibit Index which follows the page of this Current
Report on Form 8-K, which is incorporated herein by reference.
About Novan, Inc. (NASDAQ:NOVN)
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate. Novan, Inc. (NASDAQ:NOVN) Recent Trading Information
Novan, Inc. (NASDAQ:NOVN) closed its last trading session down -0.24 at 5.20 with 109,344 shares trading hands.